vs
Amneal Pharmaceuticals, Inc.（AMRX）与Custom Truck One Source, Inc.（CTOS）财务数据对比。点击上方公司名可切换其他公司
Amneal Pharmaceuticals, Inc.的季度营收约是Custom Truck One Source, Inc.的1.7倍（$722.5M vs $422.2M），Amneal Pharmaceuticals, Inc.净利率更高（10.8% vs -4.2%，领先15.0%），Amneal Pharmaceuticals, Inc.同比增速更快（3.9% vs -8.5%），过去两年Custom Truck One Source, Inc.的营收复合增速更高（14.8% vs 1.5%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Custom Truck One Source是北美领先的专用重型卡车及设备解决方案提供商，业务覆盖定制车辆制造、设备销售与租赁、售后配件供应及维保服务，主要服务基建、公用事业、建筑、能源等核心领域。
AMRX vs CTOS — 直观对比
营收规模更大
AMRX
是对方的1.7倍
$422.2M
营收增速更快
AMRX
高出12.4%
-8.5%
净利率更高
AMRX
高出15.0%
-4.2%
两年增速更快
CTOS
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $722.5M | $422.2M |
| 净利润 | $78.0M | $-17.8M |
| 毛利率 | 44.3% | 20.3% |
| 营业利润率 | 19.6% | 2.9% |
| 净利率 | 10.8% | -4.2% |
| 营收同比 | 3.9% | -8.5% |
| 净利润同比 | 410.5% | -333.7% |
| 每股收益（稀释后） | $0.19 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXCTOS
| Q1 26 | $722.5M | $422.2M | ||
| Q4 25 | $814.3M | $387.3M | ||
| Q3 25 | $784.5M | $359.9M | ||
| Q2 25 | $724.5M | $392.2M | ||
| Q1 25 | $695.4M | $307.1M | ||
| Q4 24 | $730.5M | $398.3M | ||
| Q3 24 | $702.5M | $337.5M | ||
| Q2 24 | $701.8M | $320.6M |
净利润AMRXCTOS
| Q1 26 | $78.0M | $-17.8M | ||
| Q4 25 | $35.1M | $20.9M | ||
| Q3 25 | $2.4M | $-5.8M | ||
| Q2 25 | $22.4M | $-28.4M | ||
| Q1 25 | $12.2M | $-17.8M | ||
| Q4 24 | $-31.1M | $27.6M | ||
| Q3 24 | $-156.0K | $-17.4M | ||
| Q2 24 | $6.0M | $-24.5M |
毛利率AMRXCTOS
| Q1 26 | 44.3% | 20.3% | ||
| Q4 25 | 36.5% | 31.8% | ||
| Q3 25 | 34.9% | 28.0% | ||
| Q2 25 | 39.5% | 26.1% | ||
| Q1 25 | 36.8% | 27.9% | ||
| Q4 24 | 36.0% | 29.7% | ||
| Q3 24 | 38.4% | 27.2% | ||
| Q2 24 | 35.6% | 27.8% |
营业利润率AMRXCTOS
| Q1 26 | 19.6% | 2.9% | ||
| Q4 25 | 13.8% | 13.4% | ||
| Q3 25 | 9.0% | 9.1% | ||
| Q2 25 | 15.4% | 7.1% | ||
| Q1 25 | 14.4% | 4.0% | ||
| Q4 24 | 10.4% | 16.9% | ||
| Q3 24 | 12.6% | 6.8% | ||
| Q2 24 | 13.6% | 5.5% |
净利率AMRXCTOS
| Q1 26 | 10.8% | -4.2% | ||
| Q4 25 | 4.3% | 5.4% | ||
| Q3 25 | 0.3% | -1.6% | ||
| Q2 25 | 3.1% | -7.2% | ||
| Q1 25 | 1.8% | -5.8% | ||
| Q4 24 | -4.3% | 6.9% | ||
| Q3 24 | -0.0% | -5.2% | ||
| Q2 24 | 0.9% | -7.6% |
每股收益（稀释后）AMRXCTOS
| Q1 26 | $0.19 | $-0.08 | ||
| Q4 25 | $0.10 | $0.10 | ||
| Q3 25 | $0.01 | $-0.03 | ||
| Q2 25 | $0.07 | $-0.13 | ||
| Q1 25 | $0.04 | $-0.08 | ||
| Q4 24 | $-0.10 | $0.11 | ||
| Q3 24 | $0.00 | $-0.07 | ||
| Q2 24 | $0.02 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $197.7M | $6.3M |
| 总债务越低越好 | — | $25.9M |
| 股东权益账面价值 | — | $809.1M |
| 总资产 | $3.5B | $3.4B |
| 负债/权益比越低杠杆越低 | — | 0.03× |
8季度趋势，按日历期对齐
现金及短期投资AMRXCTOS
| Q1 26 | $197.7M | $6.3M | ||
| Q4 25 | $282.0M | $6.3M | ||
| Q3 25 | $201.2M | $13.1M | ||
| Q2 25 | $71.5M | $5.3M | ||
| Q1 25 | $59.2M | $5.4M | ||
| Q4 24 | $110.6M | $3.8M | ||
| Q3 24 | $74.0M | $8.4M | ||
| Q2 24 | $43.8M | $8.1M |
总债务AMRXCTOS
| Q1 26 | — | $25.9M | ||
| Q4 25 | $2.6B | $1.6B | ||
| Q3 25 | $2.6B | $1.6B | ||
| Q2 25 | $2.2B | $1.6B | ||
| Q1 25 | $2.2B | $1.6B | ||
| Q4 24 | $2.4B | $1.5B | ||
| Q3 24 | $2.4B | $1.6B | ||
| Q2 24 | $2.4B | $1.5B |
股东权益AMRXCTOS
| Q1 26 | — | $809.1M | ||
| Q4 25 | $-70.8M | $809.1M | ||
| Q3 25 | $-109.5M | $784.7M | ||
| Q2 25 | $-112.1M | $790.1M | ||
| Q1 25 | $-131.7M | $813.4M | ||
| Q4 24 | $-109.3M | $861.3M | ||
| Q3 24 | $-93.4M | $837.5M | ||
| Q2 24 | $-57.5M | $856.7M |
总资产AMRXCTOS
| Q1 26 | $3.5B | $3.4B | ||
| Q4 25 | $3.7B | $3.4B | ||
| Q3 25 | $3.6B | $3.5B | ||
| Q2 25 | $3.4B | $3.6B | ||
| Q1 25 | $3.4B | $3.5B | ||
| Q4 24 | $3.5B | $3.5B | ||
| Q3 24 | $3.5B | $3.6B | ||
| Q2 24 | $3.5B | $3.5B |
负债/权益比AMRXCTOS
| Q1 26 | — | 0.03× | ||
| Q4 25 | — | 2.03× | ||
| Q3 25 | — | 2.10× | ||
| Q2 25 | — | 2.04× | ||
| Q1 25 | — | 1.97× | ||
| Q4 24 | — | 1.77× | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | 1.79× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
暂无分部数据
CTOS
| Equipment sales | $273.9M | 65% |
| Rental revenue | $116.3M | 28% |
| Parts sales and services | $32.1M | 8% |
